• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    aTyr Pharma, Inc. - Common Stock (NQ: ATYR )

    3.740 -0.030 (-0.80%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,051,278
    Open 3.860
    Bid (Size) 3.660 (1)
    Ask (Size) 3.790 (6)
    Prev. Close 3.770
    Today's Range 3.640 - 3.980
    52wk Range 1.420 - 3.980
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
    From aTyr Pharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +105.49%
    +105.49%
    1 Month
    +5.95%
    +5.95%
    3 Month
    +112.50%
    +112.50%
    6 Month
    +139.74%
    +139.74%
    1 Year
    +105.49%
    +105.49%

    More News

    Read More
    aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    aTyr Pharma to Present at Upcoming Investor Conferences
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    aTyr Pharma to Participate in September Investor Conferences
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2024
    Via InvestorPlace
    aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    aTyr Pharma Announces Research Study with Stanford Medicine
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
    From aTyr Pharma, Inc.
    Via GlobeNewswire
    ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2023
    Via InvestorPlace
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.